Archive for the ‘Food’ Category

Reported symptoms of food hypersensitivity and sensitization to common foods in 4-year-old children

Friday, February 6th, 2009

http://www3.interscience.wiley.com/journal/119405359/abstract?CRETRY=1&SRETRY=0

Acta Pædiatrica
Volume 97 Issue 1, Pages 85 – 90

Published Online: 11 Dec 2007

Reported symptoms of food hypersensitivity and sensitization to common foods in 4-year-old children
Eva Östblom 1,2,3 , Magnus Wickman 1,3,4 , Marianne van Hage 3,5 , Gunnar Lilja 1,2,3
1.Department of Pediatrics’, Sachs’ Children’s Hospital, Stockholm, Sweden 2.Department of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden 3.Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden 4.National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden 5.Clinical Immunology and Allergy Unit, Department of Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden
Correspondence
Eva Östblom, M.D., Department of Pediatrics, Sachs’ Children’s Hospital, S – 118 83 Stockholm, Sweden. Tel: +4686164000 | Fax: +468304571 | Email: eva.ostblom@ki.se

Supported by the Swedish Asthma and Allergy Associations Research Foundation, the Center For Allergy Research, Karolinska Institutet, the Swedish Heart and Lung Foundation, the Vardal Foundation for Health Care Sciences and Allergy Research and Stockholm County Council.
Copyright Journal Compilation © 2008 Foundation Acta Pædiatrica
KEYWORDS
BAMSE • children • food allergy • food hypersensitivity • sensitization

ABSTRACT
Aim: To characterize reported food hypersensitivity (FHS) among young children in a birth cohort.

Methods: At 4 years of age a parental questionnaire on FHS and allergic symptoms was evaluated. Blood was collected for analyses of IgE-antibodies to egg, milk, fish, wheat, peanut and soy. Complete questionnaire data was available for 3694 children (90%), and blood samples were obtained from 2563 children (63%).

Results: FHS was reported in 11% of the children (n = 397). Eczema was the most commonly reported symptom and the only symptom in half of these children. Food-related reactions from the airways, facial oedema or urticaria were reported in 198 children, and the majority of these children (75%) reported multiple symptoms. Furthermore, a combination of airway symptoms, facial oedema or urticaria together with sensitization to food suggested a more severe form of FHS. This was found in 1.6% of all children. Symptoms caused by peanut were closely associated with sensitization to peanut (p < 0.001).

Conclusions: FHS in 4-year-old children with any of asthma, rhino-conjunctivitis, facial oedema or urticaria in combination is in most cases associated to sensitization to food. This phenotype of FHS is likely to represent a more severe form of FHS.

Received
14 July 2007; revised 4 September 2007; accepted 12 September 2007.
DIGITAL OBJECT IDENTIFIER (DOI)
10.1111/j.1651-2227.2007.00556.x About DOI

Splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats

Friday, February 6th, 2009

Splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats

Abou-Donia MB, El-Masry EM, Abdel-Rahman AA, McLendon RE, Schiffman SS.

Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27708, USA. donia@duke.edu

J Toxicol Environ Health A. 2008;71(21):1415-29.

Splenda is comprised of the high-potency artificial sweetener sucralose (1.1%) and the fillers maltodextrin and glucose. Splenda was administered by oral gavage at 100, 300, 500, or 1000 mg/kg to male Sprague-Dawley rats for 12-wk, during which fecal samples were collected weekly for bacterial analysis and measurement of fecal pH. After 12-wk, half of the animals from each treatment group were sacrificed to determine the intestinal expression of the membrane efflux transporter P-glycoprotein (P-gp) and the cytochrome P-450 (CYP) metabolism system by Western blot. The remaining animals were allowed to recover for an additional 12-wk, and further assessments of fecal microflora, fecal pH, and expression of P-gp and CYP were determined. At the end of the 12-wk treatment period, the numbers of total anaerobes, bifidobacteria, lactobacilli, Bacteroides, clostridia, and total aerobic bacteria were significantly decreased; however, there was no significant treatment effect on enterobacteria. Splenda also increased fecal pH and enhanced the expression of P-gp
by 2.43-fold, CYP3A4 by 2.51-fold, and CYP2D1 by 3.49-fold. Following the 12-wk recovery period, only the total anaerobes and bifidobacteria remained significantly depressed, whereas pH values, P-
gp, and CYP3A4 and CYP2D1 remained elevated. These changes occurred at Splenda dosages that contained sucralose at 1.1-11 mg/kg (the US FDA Acceptable Daily Intake for sucralose is 5 mg/kg). Evidence indicates that a 12-wk administration of Splenda exerted numerous adverse effects, including (1) reduction in beneficial fecal microflora, (2) increased fecal pH, and (3) enhanced expression
levels of P-gp, CYP3A4, and CYP2D1, which are known to limit the bioavailability of orally administered drugs.

http://www.ncbi.nlm.nih.gov/pubmed/18800291?dopt=AbstractPlus

PMID: 18800291 [PubMed - in process]